Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
SCOLR Pharma, Inc. (SCLR)
|
Add to portfolio |
|
|
|
| Price: |
$0.00
| | Metrics |
| OS: |
49.8
|
M
| |
-451
|
% ROE
|
| Market cap: |
|
| |
-716
|
% ROIC
|
|
Net cash:
|
$77
|
k
| |
$0.00
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($5.9)
|
M
| |
|
|
|
EBIT
|
($6.3)
|
M
| |
|
|
| EPS |
($0.16)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 |
| Revenues | 0.9 | 0.9 | 1.0 | 2.0 | 2.3 | 0.6 | 0.4 | 6.6 |
| Revenue growth | 0.0% | -2.4% | -51.4% | -13.5% | 258.6% | 43.8% | -93.3% | |
| Cost of goods sold | 7.6 | 7.6 | -11.3 | 13.3 | 14.7 | 9.4 | 5.5 | 4.6 |
| Gross profit | -6.7 | -6.7 | 12.3 | -11.3 | -12.5 | -8.8 | -5.1 | 2.0 |
| Gross margin | -717.3% | -717.3% | 1279.2% | -572.5% | -547.1% | -1384.4% | -1147.1% | 30.6% |
| Sales and marketing | 0.3 | 0.2 | 0.7 | 0.9 | 0.8 | 0.3 | 0.2 | 0.5 |
| Research and development | 2.4 | 2.4 | 6.3 | 7.8 | 7.7 | 5.9 | 2.6 | 0.4 |
| General and administrative | 4.9 | 5.0 | 4.4 | 4.6 | 6.2 | 3.3 | 2.7 | 4.2 |
| EBIT | -6.7 | -6.7 | -6.4 | -11.3 | -12.5 | -8.8 | -5.1 | -3.1 |
| EBIT margin | -717.3% | -717.3% | -663.5% | -572.5% | -547.1% | -1384.4% | -1147.1% | -46.4% |
| Pre-tax income | -6.9 | -6.7 | -6.1 | -10.6 | -10.7 | -8.9 | -5.7 | -8.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -6.9 | -6.7 | -6.1 | -10.6 | -10.7 | -8.9 | -5.7 | -8.7 |
| Net margin | -734.7% | -716.3% | -640.9% | -538.5% | -471.5% | -1398.5% | -1300.4% | -132.6% |
| |
| Diluted EPS | ($0.17) | ($0.16) | ($0.15) | ($0.28) | ($0.29) | ($0.26) | ($0.19) | ($0.41) |
| Shares outstanding (diluted) | 41.1 | 41.1 | 41.1 | 38.3 | 37.2 | 34.3 | 29.8 | 21.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|